Identifying <scp>HER2</scp> from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue <scp>HER2</scp> status and predicting the efficacy of trastuzumab‐based therapy

Abstract

Serum exosomal HER2 level might serve as an effective biomarker for assessing tissue HER2 status in AGC and screening the potential patients who might benefit from anti-HER2 therapy.